AI Summary
The article discusses the results of a phase 1 study on a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, BL-B01D1, in patients with advanced solid tumors. The study found that BL-B01D1 showed preliminary antitumor activity and had an acceptable safety profile in heavily treated patients. The recommended phase 2 dose in Chinese patients was determined to be 2.5 mg/kg on days 1 and 8 every 3 weeks.
Our results suggest that BL-B01D1 has preliminary antitumour activity in extensively and heavily treated advanced solid tumours with an acceptable safety profile. Based on the safety and antitumour activity data from both phase 1a and 1b, 2·5 mg/kg on days 1 and 8 every 3 weeks was selected as the recommended phase 2 dose in Chinese patients.